drugset / Trial / NCT01110616

EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)

NCT01110616

Phase 1 Completed 25 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

The objective of this study is to test the experimental reproducibility and within-subject variability of qEEG (quantitative electroencephalogram) using two probe compounds: MK3134 and lorazepam. This study will test the hypothesis that EEG (Electroencephalogram) theta power, averaged across a topographical region of interest is decreased 6 hours after administration of MK3134 compared to placebo. The objective of this study is to test the experimental reproducibility and within-subject variability of qEEG using two probe compounds: MK3134 and lorazepam.

Timeline

Start
2010-06
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorazepam Small molecule 2 mg Oral
Subject MK3134 Unknown 25 mg Oral

Indications